Clinical Study

Alkermes Alks4230-001- A Phase 1/2 Study Of Alks 4230 Administered Subcutaneously As Monotherapy And In Combination With Pembrolizumab In Subjects With Advanced Solid Tumors

Posted Date: Jul 9, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The goal of this study is to characterize the safety and tolerability and to identify the recommended Phase 2 dose (RP2D) of ALKS 4230 administered subcutaneously (SC) as lead-in monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors, and estimate the clinical activity of combination treatment with ALKS 4230 and pembrolizumab in terms of objective response rate.


To Be Eligible: Subjects Must Have An Advanced Solid Tumor And Progressive Disease Following At Least 1 Line Of Therapy(Phase 1), Must Have Nsclc, Scchn , Squamous Tumor Agnostic, Hcc, And Sclc For Phase 2, Ecog 0 Or 1, No Hypersensitivity To Any Of Study Drug Components, No Active Or Past History Of Any Infection Or Disorder That May Impact Study Treatment


Phase 1, Solid Tumor

For More Information:

Uc Cancer Center